Sign in
UNCY Stock Price, Chart, Stats & News
Unicycive Therapeutics, Inc.
Save
153.23M
Market cap
–
Current P/E
3.44x
Forward P/E
UNCY chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -66.02% |
ROE | -184.07% |
D/E | 0.01x |
Interest coverage ratio | -500.87x |
UNCY valuation
P/E | – |
P/S | – |
P/B | 3.08x |
P/CF | -3.87x |
P/FCF | -4.60x |
P/OCF | -3.87x |
PEG | -0.78x |
EV multiple | -8.68x |
About
Unicycive Therapeutics, Inc. is a U. S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury.
Similar securities
Based on sector and market capitalization
Report issue